-
1
-
-
80051580618
-
Cancer statistics 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212-236 (2011).
-
(2011)
CA Cancer J. Clin.
, vol.61
, Issue.4
, pp. 212-236
-
-
Siegel, R.1
Ward, E.2
Brawley, O.3
Jemal, A.4
-
2
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
-
(1971)
N. Engl. J. Med.
, vol.285
, Issue.21
, pp. 1182-1186
-
-
Folkman, J.1
-
3
-
-
0015311426
-
Anti-angiogenesis: New concept for therapy of solid tumors
-
Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175(3), 409-416 (1972).
-
(1972)
Ann. Surg.
, vol.175
, Issue.3
, pp. 409-416
-
-
Folkman, J.1
-
4
-
-
0029004025
-
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
-
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146(5), 1029-1039 (1995).
-
(1995)
Am. J. Pathol.
, vol.146
, Issue.5
, pp. 1029-1039
-
-
Dvorak, H.F.1
Brown, L.F.2
Detmar, M.3
Dvorak, A.M.4
-
5
-
-
0027043136
-
Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
-
Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new signifcant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst. 84(24), 1875-1887 (1992). (Pubitemid 23004615)
-
(1992)
Journal of the National Cancer Institute
, vol.84
, Issue.24
, pp. 1875-1887
-
-
Weidner, N.1
Folkman, J.2
Pozza, F.3
Bevilacqua, P.4
Allred, E.N.5
Moore, D.H.6
Meli, S.7
Gasparini, G.8
-
6
-
-
0141988568
-
Fundamental concepts of the angiogenic process
-
DOI 10.2174/1566524033479465
-
Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3(7), 643-651 (2003). (Pubitemid 37236406)
-
(2003)
Current Molecular Medicine
, vol.3
, Issue.7
, pp. 643-651
-
-
Folkman, J.1
-
7
-
-
20544455330
-
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
-
DOI 10.1016/j.bbrc.2005.05.132, PII S0006291X05011344
-
Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333(2), 328-335 (2005). (Pubitemid 40848295)
-
(2005)
Biochemical and Biophysical Research Communications
, vol.333
, Issue.2
, pp. 328-335
-
-
Ferrara, N.1
Hillan, K.J.2
Novotny, W.3
-
8
-
-
34447108810
-
Vascular endothelial growth factor: Biology and therapeutic applications
-
DOI 10.1016/j.biocel.2007.04.010, PII S1357272507001239
-
Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int. J. Biochem. Cell Biol. 39(7-8), 1349-1357 (2007). (Pubitemid 47031045)
-
(2007)
International Journal of Biochemistry and Cell Biology
, vol.39
, Issue.7-8
, pp. 1349-1357
-
-
Ho, Q.T.1
Kuo, C.J.2
-
9
-
-
0028298129
-
Angiogenesis and breast cancer
-
Folkman J. Angiogenesis and breast cancer. J. Clin. Oncol. 12(3), 441-443 (1994). (Pubitemid 24079882)
-
(1994)
Journal of Clinical Oncology
, vol.12
, Issue.3
, pp. 441-443
-
-
Folkman, J.1
-
10
-
-
65549083899
-
A critical ana lysis of current in vitro and in vivo angiogenesis assays
-
Staton CA, Reed MW, Brown NJ. A critical ana lysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90(3), 195-221 (2009).
-
(2009)
Int. J. Exp. Pathol.
, vol.90
, Issue.3
, pp. 195-221
-
-
Staton, C.A.1
Reed, M.W.2
Brown, N.J.3
-
11
-
-
0022445670
-
Rapid colorimetric assay for cell growth and survival - Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability
-
DOI 10.1016/0022-1759(86)90368-6
-
Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89(2), 271-277 (1986). (Pubitemid 16080782)
-
(1986)
Journal of Immunological Methods
, vol.89
, Issue.2
, pp. 271-277
-
-
Denizot, F.1
Lang, R.2
-
12
-
-
2342539769
-
Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3- benzothiazin-4-one (BJ-601) on human vascular endothelial cells: G0/G1 p21-associated cell cycle arrest
-
DOI 10.1016/j.bcp.2004.02.004, PII S0006295204000929
-
Yu CH, Wu J, Su YF et al. Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells: G0/G1 p21-associated cell cycle arrest. Biochem. Pharmacol. 67(10), 1907-1916 (2004). (Pubitemid 38591379)
-
(2004)
Biochemical Pharmacology
, vol.67
, Issue.10
, pp. 1907-1916
-
-
Yu, C.-H.1
Wu, J.2
Su, Y.-F.3
Ho, P.-Y.4
Liang, Y.-C.5
Sheu, M.-T.6
Lee, W.-S.7
-
13
-
-
0021219762
-
In vitro reendothelialization of a single-cell wound: Role of microfilament bundles in rapid lamellipodia-mediated wound closure
-
Wong MK, Gotlieb AI. In vitro reendothelialization of a single-cell wound. Role of microflament bundles in rapid lamellipodia-mediated wound closure. Lab. Invest. 51(1), 75-81 (1984). (Pubitemid 14053755)
-
(1984)
Laboratory Investigation
, vol.51
, Issue.1
, pp. 75-81
-
-
Wong, M.K.K.1
Gotlieb, A.I.2
-
14
-
-
0343841187
-
The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes
-
Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J. Exp. Med. 115, 453-466 (1962).
-
(1962)
J. Exp. Med.
, vol.115
, pp. 453-466
-
-
Boyden, S.1
-
15
-
-
5444264883
-
The "chemoinvasion assay": A tool to study tumor and endothelial cell invasion of basement membranes
-
DOI 10.1387/ijdb.041822aa, Invasion in Cancer and Embryonic Development
-
Albini A, Benelli R, Noonan DM, Brigati C. The 'chemoinvasion assay': a tool to study tumor and endothelial cell invasion of basement membranes. Int. J. Dev. Biol. 48(5-6), 563-571 (2004). (Pubitemid 39360407)
-
(2004)
International Journal of Developmental Biology
, vol.48
, Issue.5-6
, pp. 563-571
-
-
Albini, A.1
Benelli, R.2
Noonan, D.M.3
Brigati, C.4
-
16
-
-
0024094113
-
Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures
-
Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107(4), 1589-1598 (1988).
-
(1988)
J. Cell Biol.
, vol.107
, Issue.4
, pp. 1589-1598
-
-
Kubota, Y.1
Kleinman, H.K.2
Martin, G.R.3
Lawley, T.J.4
-
17
-
-
70349497161
-
The endothelial cell tube formation assay on basement membrane turns 20: State of the science and the art
-
Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12(3), 267-274 (2009).
-
(2009)
Angiogenesis
, vol.12
, Issue.3
, pp. 267-274
-
-
Arnaoutova, I.1
George, J.2
Kleinman, H.K.3
Benton, G.4
-
18
-
-
23744449992
-
Matrigel: Basement membrane matrix with biological activity
-
DOI 10.1016/j.semcancer.2005.05.004, PII S1044579X05000313
-
Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 15(5), 378-386 (2005). (Pubitemid 41140305)
-
(2005)
Seminars in Cancer Biology
, vol.15
, Issue.SPEC. ISS.
, pp. 378-386
-
-
Kleinman, H.K.1
Martin, G.R.2
-
19
-
-
77949439845
-
In vitro angiogenesis: Endothelial cell tube formation on gelled basement membrane extract
-
Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat. Protoc. 5(4), 628-635 (2010).
-
(2010)
Nat. Protoc.
, vol.5
, Issue.4
, pp. 628-635
-
-
Arnaoutova, I.1
Kleinman, H.K.2
-
20
-
-
33947704049
-
In vitro models of angiogenesis
-
DOI 10.1007/s00268-006-0763-4
-
Ucuzian AA, Greisler HP. In vitro models of angiogenesis. World J. Surg. 31(4), 654-663 (2007). (Pubitemid 46496237)
-
(2007)
World Journal of Surgery
, vol.31
, Issue.4
, pp. 654-663
-
-
Ucuzian, A.A.1
Greisler, H.P.2
-
21
-
-
52049114102
-
In vitro three dimensional collagen matrix models of endothelial lumen formation during vasculogenesis and angiogenesis
-
Koh W, Stratman AN, Sacharidou A, Davis GE. In vitro three dimensional collagen matrix models of endothelial lumen formation during vasculogenesis and angiogenesis. Methods Enzymol. 443, 83-101 (2008).
-
(2008)
Methods Enzymol.
, vol.443
, pp. 83-101
-
-
Koh, W.1
Stratman, A.N.2
Sacharidou, A.3
Davis, G.E.4
-
22
-
-
69249233604
-
Advancing science and technology via 3D culture on basement membrane matrix
-
Benton G, George J, Kleinman HK, Arnaoutova IP. Advancing science and technology via 3D culture on basement membrane matrix. J. Cell. Physiol. 221(1), 18-25 (2009).
-
(2009)
J. Cell. Physiol.
, vol.221
, Issue.1
, pp. 18-25
-
-
Benton, G.1
George, J.2
Kleinman, H.K.3
Arnaoutova, I.P.4
-
23
-
-
52049089123
-
The aortic ring model of angiogenesis
-
Aplin AC, Fogel E, Zorzi P, Nicosia RF. The aortic ring model of angiogenesis. Methods Enzymol. 443, 119-136 (2008).
-
(2008)
Methods Enzymol.
, vol.443
, pp. 119-136
-
-
Aplin, A.C.1
Fogel, E.2
Zorzi, P.3
Nicosia, R.F.4
-
24
-
-
42949085656
-
Modeling lymphangiogenesis in a three-dimensional culture system
-
DOI 10.1038/nmeth.1205, PII NMETH.1205
-
Bruyere F, Melen-Lamalle L, Blacher S et al. Modeling lymphangiogenesis in a three-dimensional culture system. Nat. Methods 5(5), 431-437 (2008). (Pubitemid 351619102)
-
(2008)
Nature Methods
, vol.5
, Issue.5
, pp. 431-437
-
-
Bruyere, F.1
Melen-Lamalle, L.2
Blacher, S.3
Roland, G.4
Thiry, M.5
Moons, L.6
Frankenne, F.7
Carmeliet, P.8
Alitalo, K.9
Libert, C.10
Sleeman, J.P.11
Foidart, J.-M.12
Noel, A.13
-
25
-
-
0037406938
-
Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay
-
Guedez L, Rivera AM, Salloum R et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am. J. Pathol. 162(5), 1431-1439 (2003). (Pubitemid 36512825)
-
(2003)
American Journal of Pathology
, vol.162
, Issue.5
, pp. 1431-1439
-
-
Guedez, L.1
Rivera, A.M.2
Salloum, R.3
Miller, M.L.4
Diegmueller, J.J.5
Bungay, P.M.6
Stetler-Stevenson, W.G.7
-
26
-
-
4344663950
-
A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay
-
Miller WJ, Kayton ML, Patton A et al. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay J. Transl. Med. 2(1), 4 (2004).
-
(2004)
J. Transl. Med.
, vol.2
, Issue.1
, pp. 4
-
-
Miller, W.J.1
Kayton, M.L.2
Patton, A.3
-
27
-
-
38449100203
-
The mouse cornea micropocket angiogenesis assay
-
Rogers MS, Birsner AE, DAmato RJ. The mouse cornea micropocket angiogenesis assay Nat. Protoc. 2(10), 2545-2550 (2007).
-
(2007)
Nat. Protoc.
, vol.2
, Issue.10
, pp. 2545-2550
-
-
Rogers, M.S.1
Birsner, A.E.2
Damato, R.J.3
-
28
-
-
77449129151
-
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
-
Traina TA, Rugo HS, Caravelli JF et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J. Clin. Oncol. 28(4), 628-633 (2009).
-
(2009)
J. Clin. Oncol.
, vol.28
, Issue.4
, pp. 628-633
-
-
Traina, T.A.1
Rugo, H.S.2
Caravelli, J.F.3
-
29
-
-
33744812137
-
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
-
DOI 10.1158/1078-0432.CCR-05-2603
-
Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12(10), 3124-3129 (2006). (Pubitemid 43837360)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.10
, pp. 3124-3129
-
-
Ramaswamy, B.1
Elias, A.D.2
Kelbick, N.T.3
Dudley, A.4
Morrow, M.5
Hauger, M.6
Allen, J.7
Rhoades, C.8
Kendra, K.9
Chen, H.X.10
Gail Eckhardt, S.11
Shapiro, C.L.12
-
30
-
-
59449097074
-
A Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
-
Dickler MN, Rugo HS, Eberle CA et al. A Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 14(23), 7878-7883 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.23
, pp. 7878-7883
-
-
Dickler, M.N.1
Rugo, H.S.2
Eberle, C.A.3
-
31
-
-
59449108734
-
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
-
Burstein HJ, Chen YH, Parker LM et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 14(23), 7871-7877 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.23
, pp. 7871-7877
-
-
Burstein, H.J.1
Chen, Y.H.2
Parker, L.M.3
-
32
-
-
54449099774
-
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
-
Dellapasqua S, Bertolini F, Bagnardi V et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26(30), 4899-4905 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.30
, pp. 4899-4905
-
-
Dellapasqua, S.1
Bertolini, F.2
Bagnardi, V.3
-
33
-
-
57049164414
-
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer
-
Garcia-Saenz JA, Martin M, Calles A et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer. J. Chemother. 20(5), 632-639 (2008).
-
(2008)
J. Chemother.
, vol.20
, Issue.5
, pp. 632-639
-
-
Garcia-Saenz, J.A.1
Martin, M.2
Calles, A.3
-
34
-
-
77949503823
-
North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
-
Perez EA, Hillman DW, Dentchev T et al. North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann. Oncol. 21(2), 269-274 (2009).
-
(2009)
Ann. Oncol.
, vol.21
, Issue.2
, pp. 269-274
-
-
Perez, E.A.1
Hillman, D.W.2
Dentchev, T.3
-
35
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
DOI 10.1200/JCO.2005.05.098
-
Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005). (Pubitemid 46224178)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
Cobleigh, M.A.4
Marcom, P.K.5
Fehrenbacher, L.6
Dickler, M.7
Overmoyer, B.A.8
Reimann, J.D.9
Sing, A.P.10
Langmuir, V.11
Rugo, H.S.12
-
36
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
-
(2007)
N. Engl. J. Med.
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
37
-
-
77954700380
-
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239-3247 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.20
, pp. 3239-3247
-
-
Miles, D.W.1
Chan, A.2
Dirix, L.Y.3
-
38
-
-
80054883209
-
Effcacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
-
Pivot X, Schneeweiss A, Verma S et al. Effcacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur. J. Cancer 12, 12 (2011).
-
(2011)
Eur. J. Cancer
, vol.12
, pp. 12
-
-
Pivot, X.1
Schneeweiss, A.2
Verma, S.3
-
39
-
-
79953874259
-
RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29(10), 1252-1260 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.10
, pp. 1252-1260
-
-
Robert, N.J.1
Dieras, V.2
Glaspy, J.3
-
40
-
-
81155123190
-
RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the effcacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Brufsky AM, Hurvitz S, Perez E et al. RIBBON-2: a randomized, double-blind, placebo-controlled, Phase III trial evaluating the effcacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 29(32), 4286-4293 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.32
, pp. 4286-4293
-
-
Brufsky, A.M.1
Hurvitz, S.2
Perez, E.3
-
41
-
-
84856806836
-
First results of AVEREL, a randomized Phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
-
Gianni L, Romieu G, Lichinitser M et al. First results of AVEREL, a randomized Phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res. (Abstract S4-8) (2011).
-
(2011)
Cancer Res. (Abstract S4-8)
-
-
Gianni, L.1
Romieu, G.2
Lichinitser, M.3
-
42
-
-
33644863001
-
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
-
DOI 10.1200/JCO.2005.03.4645
-
Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with infammatory and locally advanced breast cancer. J. Clin. Oncol. 24(5), 769-777 (2006). (Pubitemid 46622044)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.5
, pp. 769-777
-
-
Wedam, S.B.1
Low, J.A.2
Yang, S.X.3
Chow, C.K.4
Choyke, P.5
Danforth, D.6
Hewitt, S.M.7
Berman, A.8
Steinberg, S.M.9
Liewehr, D.J.10
Plehn, J.11
Doshi, A.12
Thomasson, D.13
McCarthy, N.14
Koeppen, H.15
Sherman, M.16
Zujewski, J.17
Camphausen, K.18
Chen, H.19
Swain, S.M.20
more..
-
43
-
-
68949111240
-
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Effcacy and safety in a Phase II pilot study Eur
-
Greil R, Moik M, Reitsamer R et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: effcacy and safety in a Phase II pilot study Eur. J. Surg. Oncol. 35(10), 1048-1054 (2009).
-
(2009)
J. Surg. Oncol.
, vol.35
, Issue.10
, pp. 1048-1054
-
-
Greil, R.1
Moik, M.2
Reitsamer, R.3
-
44
-
-
61749103127
-
Infusional fuorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
-
Balduzzi A, Montagna E, Bagnardi V et al. Infusional fuorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs 20(3), 197-203 (2009).
-
(2009)
Anticancer Drugs
, vol.20
, Issue.3
, pp. 197-203
-
-
Balduzzi, A.1
Montagna, E.2
Bagnardi, V.3
-
45
-
-
62349110279
-
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic biomarkers
-
Baar J, Silverman P, Lyons J et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin. Cancer Res. 15(10), 3583-3590 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.10
, pp. 3583-3590
-
-
Baar, J.1
Silverman, P.2
Lyons, J.3
-
46
-
-
84856253589
-
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
-
Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366, 310-320 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 310-320
-
-
Bear, H.D.1
Tang, G.2
Rastogi, P.3
-
47
-
-
84856291930
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
-
von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366(4), 299-309 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.4
, pp. 299-309
-
-
Von Minckwitz, G.1
Eidtmann, H.2
Rezai, M.3
-
48
-
-
73349123799
-
Bevacizumab and breast cancer: Current therapeutic progress and future perspectives
-
Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev. Anticancer Ther. 9(12), 1715-1725 (2009).
-
(2009)
Expert Rev. Anticancer Ther.
, vol.9
, Issue.12
, pp. 1715-1725
-
-
Yang, S.X.1
-
49
-
-
76749151794
-
The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer
-
Keefe SM, Demichele A. The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer. Curr. Oncol. Rep. 12(1), 22-25 (2010).
-
(2010)
Curr. Oncol. Rep.
, vol.12
, Issue.1
, pp. 22-25
-
-
Keefe, S.M.1
Demichele, A.2
-
50
-
-
74649087126
-
Bevacizumab in the treatment of breast cancer
-
Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP. Bevacizumab in the treatment of breast cancer. Cancer Treat. Rev. 36(1), 75-82 (2010).
-
(2010)
Cancer Treat. Rev.
, vol.36
, Issue.1
, pp. 75-82
-
-
Koutras, A.K.1
Fountzilas, G.2
Makatsoris, T.3
Peroukides, S.4
Kalofonos, H.P.5
-
51
-
-
82455199216
-
Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
-
Smith I, Pierga JY, Biganzoli L et al. Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res. Treat. 130(1), 133-143 (2011).
-
(2011)
Breast Cancer Res. Treat.
, vol.130
, Issue.1
, pp. 133-143
-
-
Smith, I.1
Pierga, J.Y.2
Biganzoli, L.3
-
52
-
-
80052428282
-
First-line bevacizumab-containing therapy for breast cancer: Results in patients aged >=70 years treated in the ATHENA study
-
Biganzoli L, Di Vincenzo E, Jiang Z et al. First-line bevacizumab-containing therapy for breast cancer: results in patients aged >=70 years treated in the ATHENA study Ann. Oncol. 23(1), 111-118 (2012).
-
(2012)
Ann. Oncol.
, vol.23
, Issue.1
, pp. 111-118
-
-
Biganzoli, L.1
Di Vincenzo, E.2
Jiang, Z.3
-
53
-
-
1842543455
-
HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential modiated by vascular endothelial growth factor (VEGF)
-
Epstein M, Ayala R, Tchekmedyian N, Borgstrom P, Pegram MD, Slamon D. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential modiated by vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat. 76, S143-S143 (2002).
-
(2002)
Breast Cancer Res. Treat.
, vol.76
-
-
Epstein, M.1
Ayala, R.2
Tchekmedyian, N.3
Borgstrom, P.4
Pegram, M.D.5
Slamon, D.6
-
54
-
-
21044443432
-
Phase i combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vasucular endothelial growth factor (VEGF)
-
Pegram M, Yeon C, Ku N, Gaudreault J, Slamon D. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vasucular endothelial growth factor (VEGF). Breast Cancer Res. Treat. 88, S124-S125 (2004).
-
(2004)
Breast Cancer Res. Treat.
, vol.88
-
-
Pegram, M.1
Yeon, C.2
Ku, N.3
Gaudreault, J.4
Slamon, D.5
-
55
-
-
79952083872
-
Congestive heart failure risk in patients with breast cancer treated with bevacizumab
-
Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J. Clin. Oncol. 29(6), 632-638 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.6
, pp. 632-638
-
-
Choueiri, T.K.1
Mayer, E.L.2
Je, Y.3
-
57
-
-
77956646251
-
Lymphangiogenesis: A new player in cancer progression
-
Nagahashi M, Ramachandran S, Rashid OM, Takabe K. Lymphangiogenesis: a new player in cancer progression. World J. Gastroenterol 16(32), 4003-4012 (2010).
-
(2010)
World J. Gastroenterol
, vol.16
, Issue.32
, pp. 4003-4012
-
-
Nagahashi, M.1
Ramachandran, S.2
Rashid, O.M.3
Takabe, K.4
-
58
-
-
76749083490
-
Lymphangiogenesis: Molecular mechanisms and future promise
-
Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140(4), 460-476 (2010).
-
(2010)
Cell
, vol.140
, Issue.4
, pp. 460-476
-
-
Tammela, T.1
Alitalo, K.2
-
59
-
-
70349330902
-
Lymphangiogenesis and cancer metastasis
-
Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J. Cell. Mol. Med. 13(8A), 1405-1416 (2009).
-
(2009)
J. Cell. Mol. Med.
, vol.13
, Issue.8 A
, pp. 1405-1416
-
-
Mumprecht, V.1
Detmar, M.2
-
60
-
-
34548685224
-
Perimuscular connective tissue contains more and larger lymphatic vessels than the shallower layers in human gallbladders
-
Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Hatakeyama K. Perimuscular connective tissue contains more and larger lymphatic vessels than the shallower layers in human gallbladders. World J. Gastroenterol. 13(33), 4480-4483 (2007). (Pubitemid 47412411)
-
(2007)
World Journal of Gastroenterology
, vol.13
, Issue.33
, pp. 4480-4483
-
-
Nagahashi, M.1
Shirai, Y.2
Wakai, T.3
Sakata, J.4
Ajioka, Y.5
Hatakeyama, K.6
-
61
-
-
46049109335
-
Tumor lymphangiogenesis and melanoma metastasis
-
DOI 10.1002/jcp.21494
-
Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J. Cell Physiol. 216(2), 347-354 (2008). (Pubitemid 351898461)
-
(2008)
Journal of Cellular Physiology
, vol.216
, Issue.2
, pp. 347-354
-
-
Rinderknecht, M.1
Detmar, M.2
-
62
-
-
33845664546
-
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours
-
DOI 10.1038/sj.bjc.6603445, PII 6603445
-
Van der Auwera I, Cao Y, Tille JC et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br. J. Cancer 95(12), 1611-1625 (2006). (Pubitemid 44950785)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.12
, pp. 1611-1625
-
-
Van Der Auwera, I.1
Cao, Y.2
Tille, J.C.3
Pepper, M.S.4
Jackson, D.G.5
Fox, S.B.6
Harris, A.L.7
Dirix, L.Y.8
Vermeulen, P.B.9
-
63
-
-
0242324035
-
Lymphangiogenesis and tumor metastasis
-
DOI 10.1007/s00441-003-0748-7
-
Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 314(1), 167-177 (2003). (Pubitemid 37409922)
-
(2003)
Cell and Tissue Research
, vol.314
, Issue.1
, pp. 167-177
-
-
Pepper, M.S.1
Tille, J.-C.2
Nisato, R.3
Skobe, M.4
-
64
-
-
30744477450
-
Lymphangiogenesis in development and human disease
-
DOI 10.1038/nature04480, PII NATURE04480
-
Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 438(7070), 946-953 (2005). (Pubitemid 43093960)
-
(2005)
Nature
, vol.438
, Issue.7070
, pp. 946-953
-
-
Alitalo, K.1
Tammela, T.2
Petrova, T.V.3
-
65
-
-
21144437844
-
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels
-
DOI 10.1158/0008-5472.CAN-04-4576
-
He Y, Rajantie I, Pajusola K et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65(11), 4739-4746 (2005). (Pubitemid 40740810)
-
(2005)
Cancer Research
, vol.65
, Issue.11
, pp. 4739-4746
-
-
He, Y.1
Rajantie, I.2
Pajusola, K.3
Jeltsch, M.4
Holopainen, T.5
Yla-Herttuala, S.6
Harding, T.7
Jooss, K.8
Takahashi, T.9
Alitalo, K.10
-
66
-
-
33748075460
-
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications
-
DOI 10.1158/0008-5472.CAN-06-1392
-
Hoshida T, Isaka N, Hagendoorn J et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66(16), 8065-8075 (2006). (Pubitemid 44299172)
-
(2006)
Cancer Research
, vol.66
, Issue.16
, pp. 8065-8075
-
-
Hoshida, T.1
Isaka, N.2
Hagendoorn, J.3
Di Tomaso, E.4
Chen, Y.-L.5
Pytowski, B.6
Fukumura, D.7
Padera, T.P.8
Jain, R.K.9
-
67
-
-
33846857321
-
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites
-
DOI 10.1182/blood-2006-05-021758
-
Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109(3), 1010-1017 (2007). (Pubitemid 46220646)
-
(2007)
Blood
, vol.109
, Issue.3
, pp. 1010-1017
-
-
Hirakawa, S.1
Brown, L.F.2
Kodama, S.3
Paavonen, K.4
Alitalo, K.5
Detmar, M.6
-
68
-
-
17144402207
-
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
-
DOI 10.1084/jem.20041896
-
Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201(7), 1089-1099 (2005). (Pubitemid 40524677)
-
(2005)
Journal of Experimental Medicine
, vol.201
, Issue.7
, pp. 1089-1099
-
-
Hirakawa, S.1
Kodama, S.2
Kunstfeld, R.3
Kajiya, K.4
Brown, L.F.5
Detmar, M.6
-
69
-
-
33751275549
-
Preparing the "soil": The primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells
-
DOI 10.1158/0008-5472.CAN-06-2977
-
Qian CN, Berghuis B, Tsarfaty G et al. Preparing the 'soil': the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 66(21), 10365-10376 (2006). (Pubitemid 44799756)
-
(2006)
Cancer Research
, vol.66
, Issue.21
, pp. 10365-10376
-
-
Qian, C.-N.1
Berghuis, B.2
Tsarfaty, G.3
Bruch, M.4
Kort, E.J.5
Ditlev, J.6
Tsarfaty, I.7
Hudson, E.8
Jackson, D.G.9
Petillo, D.10
Chen, J.11
Resau, J.H.12
Teh, B.T.13
-
70
-
-
30944446883
-
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
-
DOI 10.1038/ncponc0403, PII N0403
-
Jain RK, Duda DG, Clark JW, Loeffer JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006). (Pubitemid 43108832)
-
(2006)
Nature Clinical Practice Oncology
, vol.3
, Issue.1
, pp. 24-40
-
-
Jain, R.K.1
Duda, D.G.2
Clark, J.W.3
Loeffler, J.S.4
-
71
-
-
79251473728
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer
-
Jubb AM, Miller KD, Rugo HS et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin. Cancer Res. 17(2), 372-381 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, Issue.2
, pp. 372-381
-
-
Jubb, A.M.1
Miller, K.D.2
Rugo, H.S.3
-
72
-
-
78649992510
-
Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization
-
Tvorogov D, Anisimov A, Zheng W et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 18(6), 630-640 (2010).
-
(2010)
Cancer Cell
, vol.18
, Issue.6
, pp. 630-640
-
-
Tvorogov, D.1
Anisimov, A.2
Zheng, W.3
-
73
-
-
33645046619
-
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2
-
Roberts N, Kloos B, Cassella M et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66(5), 2650-2657 (2006).
-
(2006)
Cancer Res.
, vol.66
, Issue.5
, pp. 2650-2657
-
-
Roberts, N.1
Kloos, B.2
Cassella, M.3
-
74
-
-
77955512358
-
Lymphangiogenesis and lymphatic metastasis in breast cancer
-
Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17(4), 229-251 (2010).
-
(2010)
Pathophysiology
, vol.17
, Issue.4
, pp. 229-251
-
-
Ran, S.1
Volk, L.2
Hall, K.3
Flister, M.J.4
-
75
-
-
77954682879
-
Ramucirumab (IMC-1121B): A novel attack on angiogenesis
-
Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol. 6(7), 1085-1094 (2010).
-
(2010)
Future Oncol.
, vol.6
, Issue.7
, pp. 1085-1094
-
-
Spratlin, J.L.1
Mulder, K.E.2
Mackey, J.R.3
-
76
-
-
81255188905
-
The lymphatic vasculature in disease
-
Alitalo K. The lymphatic vasculature in disease. Nat. Med. 17(11), 1371-1380 (2011).
-
(2011)
Nat. Med.
, vol.17
, Issue.11
, pp. 1371-1380
-
-
Alitalo, K.1
|